151 results
Page 5 of 8
424B5
myhy83csm k2ql1pg0y
21 Feb 20
Prospectus supplement for primary offering
4:26pm
424B5
eb1k v6nui
20 Feb 20
Prospectus supplement for primary offering
5:28pm
8-K
EX-4.1
omcxwc1d
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-4.2
80lrvxdc 2xb4c8dg5
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
xqszb
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
gf2v0wwzc oew
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
1nuhy
8 Jan 20
Results of Operations and Financial Condition
4:31pm
8-K
EX-99.1
47bsb1j 4gx
14 Nov 19
Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
4:38pm
8-K
EX-1.1
ldk026jkhq7 5eb
8 Nov 19
Entry into a Material Definitive Agreement
4:38pm
424B5
cq5lg
8 Nov 19
Prospectus supplement for primary offering
4:34pm
8-K
EX-99.1
bg2fseid 3cbto2b
31 Oct 19
Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval
4:30pm
8-K
EX-99.1
haa3peobs
28 Oct 19
Agile Therapeutics Reports Third Quarter 2019 Financial Results
8:10am
8-K
EX-1.1
00sf2xqwybbt4 libl
2 Aug 19
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
4:50pm
424B5
2zqkq1u4
2 Aug 19
Prospectus supplement for primary offering
4:40pm
424B5
xnd8q
1 Aug 19
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
boi6ydl0iwhw
1 Aug 19
Agile Therapeutics Reports Second Quarter 2019 Financial Results
8:14am
8-K
EX-99.1
wntk3pf886 q98gaoxjt
22 Jul 19
Agile Therapeutics Appoints Chief Financial Officer
5:23pm